Abstract/Description

Research has shown that incretin-mimetic agents approved and used for weight loss may help treat heart failure by improving their quality of life and functional capacity. Whether differences exist between these agents in the HFpEF population has not been tested before. Our study set out to see if these agents affected risk of all-cause mortality and further heart failure related hospitalizations in patients with obesity-related HFpEF and whether differences exist among them.

Presenting Author Name/s

Leila Humphreys

Faculty Advisor/Mentor

Salvatore Carbone

Faculty Advisor/Mentor Email

scarbone@odu.edu

Faculty Advisor/Mentor Department

Nutrition at Old Dominion University

College/School/Affiliation

Other

Download

Included in

Public Health Commons

Share

COinS
 

Mortality and Heart Failure Exacerbations with Incretin-mimetic Drugs for Weight Loss in Patients with Obesity-related Heart Failure with preserved Ejection Fraction

Research has shown that incretin-mimetic agents approved and used for weight loss may help treat heart failure by improving their quality of life and functional capacity. Whether differences exist between these agents in the HFpEF population has not been tested before. Our study set out to see if these agents affected risk of all-cause mortality and further heart failure related hospitalizations in patients with obesity-related HFpEF and whether differences exist among them.